Evidence map›Paper›PMID 42074071›Full record

ArticleInternational journal of molecular sciences2026

The Role of MNX1-AS1 in Ovarian Cancer Resistance and Tumor Progression via RNA-RNA Interactions.

Alvaro Gutierrez, Carolina Larronde, Salomé Silva, Constanza Castro, Rodrigo Maldonado, Daniela León, Juan Machuca, Carmen Gloria Ili, Priscilla Brebi, Kurt Buchegger and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alvaro GutierrezLaboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
Carolina LarrondeLaboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
Salomé SilvaPrograma de Doctorado en Ciencias de Recursos Naturales, Universidad de La Frontera, Temuco 4811230, Chile.
Constanza CastroDepartamento de Ciencias Básicas, Facultad de Medicina. Universidad de La Frontera, Temuco 4810296, Chile.
Rodrigo MaldonadoFacultad de Ciencias, Universidad San Sebastián, Valdivia 5110246, Chile.ORCID 0000-0002-4648-6697
Daniela LeónLaboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.
Juan MachucaPrograma de Doctorado En Ciencias Biomédicas, Facultad Ciencias de la Salud, UniversidadAutónoma de Chile, Temuco 4780000, Chile..ORCID 0009-0007-5618-0302
Carmen Gloria IliLaboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.ORCID 0000-0002-4009-4406
Priscilla BrebiLaboratory of Integrative Biology, Centro de Excelencia en Medicina Traslacional, Scientific and Technological Bioresource Nucleus (CEMT-BIOREN), Universidad de La Frontera, Temuco 4810296, Chile.ORCID 0000-0002-3896-146X
Kurt BucheggerMillenium Institute of Immunology and Immunotherapy, Santiago 8331150, Chile.ORCID 0000-0002-3872-2522
Tamara ViscarraFacultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Temuco 4780000, Chile.ORCID 0000-0001-7029-9747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) remains one of the deadliest gynecological malignancies, largely due to late diagnosis and the emergence of resistance to platinum-based chemotherapy. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators of tumor progression and therapeutic adaptation. In this study, we performed integrative transcriptomic profiling of patient-derived TCGA ovarian tumor samples and carboplatin-resistant A2780 (CBDCA-R-A2780) cells to identify lncRNAs whose dysregulation overlaps between a cell-line resistance model and patient tumors. Our analyses revealed extensive transcriptional remodeling across both datasets, with

Indexed as

Drug Resistance, NeoplasmHomeodomain ProteinsOvarian NeoplasmsRNA, Long NoncodingTranscription FactorsCell Line, TumorDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicroRNAsRNA, Competitive EndogenousHomeodomain ProteinsMicroRNAsMNX1 protein, humanRNA, Competitive EndogenousRNA, Long NoncodingTranscription Factorschemoresistanceepithelial–mesenchymal transitionlncRNAMNX1–AS1ovarian cancer

Identifiers

PMID42074071
PMCPMC13116493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.